摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-ethylphenyl)propane-1,2-dione | 99865-21-1

中文名称
——
中文别名
——
英文名称
1-(4-ethylphenyl)propane-1,2-dione
英文别名
1-(4-ethyl-phenyl)-propane-1,2-dione;1-(4-Aethyl-phenyl)-propan-1,2-dion;Methyl-(4-aethyl-phenyl)-glyoxal;1-Aethyl-4-pyruvyl-benzol;1-(4-Ethylphenyl)propane-1,2-dione
1-(4-ethylphenyl)propane-1,2-dione化学式
CAS
99865-21-1
化学式
C11H12O2
mdl
——
分子量
176.215
InChiKey
LNDOIKAFXOEWIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    138-140 °C(Press: 20 Torr)
  • 密度:
    1.052±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    34.1
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Palladium-Catalyzed Synthesis of 1,2-Diketones from Aryl Halides and Organoaluminum Reagents Using <i>tert</i>-Butyl Isocyanide as the CO Source
    作者:Bo Chen、Xiao-Feng Wu
    DOI:10.1021/acs.orglett.9b04414
    日期:2020.1.17
    In this work, an interesting and practical procedure for the synthesis of 1,2-diketones from aryl halides and organoaluminum reagents has been developed. Employing tert-butyl isocyanide as the CO source and palladium as the catalyst, the desired 1,2-diketones were isolated in good to excellent yields with good functional group tolerance. Concerning the reaction partners, besides aryl halides, both
    在这项工作中,从芳基卤化物和有机铝试剂合成1,2-二的有趣且实用的程序已经开发出来。使用异氰酸叔丁基作为CO源,使用作为催化剂,以良好的收率和良好的官能团耐受性分离出所需的1,2-二。关于反应伙伴,除​​芳基卤化物外,烷基和芳基试剂在这里都是合适的底物。
  • [EN] IMIDAZOLE-BASED ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS À BASE D'IMIDAZOLE
    申请人:PROCOMCURE BIOTECH GMBH
    公开号:WO2016087618A1
    公开(公告)日:2016-06-09
    The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.
    本发明涉及新型治疗剂,适用于治疗哺乳动物疾病,特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含上述剂的药物组合物在治疗哺乳动物的医疗状况中的使用,特别是在治疗微生物感染中的使用。本发明的剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊意义。
  • [EN] NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES À BASE D'IMIDAZOLE
    申请人:PROCOMCURE BIOTECH GMBH
    公开号:WO2016087615A1
    公开(公告)日:2016-06-09
    The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.
    本发明涉及一种新型化合物,其化学式为(I),适用于作为治疗剂用于治疗哺乳动物疾病,特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含所述治疗剂的药物组合物在治疗哺乳动物的医疗状况中的使用,特别是在治疗微生物感染方面的使用。本发明的治疗剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊的相关性。本发明还涉及制备所述治疗剂的方法。
  • Imidazole-based heterocyclic compounds
    申请人:Procomcure Biotech GmbH
    公开号:US10314820B2
    公开(公告)日:2019-06-11
    The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.
    本发明涉及适用于治疗哺乳动物疾病的新型式(I)化合物,特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含上述制剂的药物组合物在治疗哺乳动物疾病中的用途,特别是在治疗微生物感染中的用途。本发明的制剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特别重要的意义。本发明还涉及上述制剂的制造工艺。
  • Imidazole-based antimicrobial agents
    申请人:Procomcure Biotech GmbH
    公开号:US10322110B2
    公开(公告)日:2019-06-18
    The present invention relates to therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. In one particular embodiment, the pharmaceutical composition can have the structural moiety of formula (I) or a pharmaceutically-acceptable salt of said compound: wherein group A is selected from the formulae Group B is aryl, R1 is an optionally substituted aryl ring, an optionally substituted benzyl ring, CH3, or C2 to 6 alkyl, and R2 is hydrogen, an alkyl group, a halogen, or —(CH2)nN(CH3)2 where n is an integer from 1 to 3.
    本发明涉及适用于治疗哺乳动物微生物感染的治疗剂。本发明还涉及包含上述制剂的药物组合物在治疗哺乳动物的病症,特别是治疗微生物感染中的用途。本发明的制剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊意义。在一个特定的实施方案中,药物组合物可以具有式(I)的结构分子或所述化合物的药学上可接受的盐: 其中 A 组选自式 B 组为芳基,R1 为任选取代的芳基环、任选取代的苄基环、CH3 或 C2 至 6 烷基,R2 为、烷基、卤素或-(CH2)nN( )2,其中 n 为 1 至 3 的整数。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫